Paper41008918
PARP3 Promotes AML Progression via Activation of PI3K/AKT/mTOR Signaling.
Cao T and 6 others. Cancers (Basel), 2025. Cited by 1 paper, by iCite.
Cite this record
ConductScience Library. PARP3 Promotes AML Progression via Activation of PI3K/AKT/mTOR Signaling. Papers, record 41008918. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41008918
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| No.25JRRA1029 | Gansu Province Youth Science and Technology Fund program | PubMed |
Source PubMed
References49
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 35562747 | Molecular profiling and clinical implications of patients with acute myeloid leukemia and extramedullary manifestations. | J Hematol Oncol | 2022 | https://conductscience.org/library/papers/35562747 | PubMed |
| 2 | 37272257 | Acute myeloid leukemia (AML)-derived mesenchymal stem cells induce chemoresistance and epithelial-mesenchymal transition-like program in AML through IL-6/JAK2/STAT3 signaling. | Cancer Sci | 2023 | https://conductscience.org/library/papers/37272257 | PubMed |
| 3 | 37596643 | PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer. | Mol Cancer | 2023 | https://conductscience.org/library/papers/37596643 | PubMed |
| 4 | 16924674 | PARP-3 associates with polycomb group bodies and with components of the DNA damage repair machinery. | J Cell Biochem | 2007 | https://conductscience.org/library/papers/16924674 | PubMed |
| 5 | 36109561 | PARP3 supervises G9a-mediated repression of adhesion and hypoxia-responsive genes in glioblastoma cells. | Sci Rep | 2022 | https://conductscience.org/library/papers/36109561 | PubMed |
| 6 | 38830565 | Enhancing cisplatin drug sensitivity through PARP3 inhibition: The influence on PDGF and G-coupled signal pathways in cancer. | Chem Biol Interact | 2024 | https://conductscience.org/library/papers/38830565 | PubMed |
| 7 | 27530147 | PARP3 is a sensor of nicked nucleosomes and monoribosylates histone H2B(Glu2). | Nat Commun | 2016 | https://conductscience.org/library/papers/27530147 | PubMed |
| 8 | 21211721 | PARP-3 and APLF function together to accelerate nonhomologous end-joining. | Mol Cell | 2011 | https://conductscience.org/library/papers/21211721 | PubMed |
| 9 | 35797463 | Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. | Blood | 2022 | https://conductscience.org/library/papers/35797463 | PubMed |
| 10 | 21270334 | Poly(ADP-ribose) polymerase 3 (PARP3), a newcomer in cellular response to DNA damage and mitotic progression. | Proc Natl Acad Sci U S A | 2011 | https://conductscience.org/library/papers/21270334 | PubMed |
| 11 | 39189367 | PARP enzymes and mono-ADP-ribosylation: advancing the connection from interferon-signalling to cancer biology. | Expert Rev Mol Med | 2024 | https://conductscience.org/library/papers/39189367 | PubMed |
| 12 | 25322685 | Dual PI3K/mTOR inhibition shows antileukemic activity in MLL-rearranged acute myeloid leukemia. | Leukemia | 2015 | https://conductscience.org/library/papers/25322685 | PubMed |
| 13 | 35732831 | The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. | Leukemia | 2022 | https://conductscience.org/library/papers/35732831 | PubMed |
| 14 | 28447610 | PARP3 is a promoter of chromosomal rearrangements and limits G4 DNA. | Nat Commun | 2017 | https://conductscience.org/library/papers/28447610 | PubMed |
| 15 | 32326335 | The PI3K-Akt-mTOR Signaling Pathway in Human Acute Myeloid Leukemia (AML) Cells. | Int J Mol Sci | 2020 | https://conductscience.org/library/papers/32326335 | PubMed |
| 16 | 37803061 | Expression profiling of extramedullary acute myeloid leukemia suggests involvement of epithelial-mesenchymal transition pathways. | Leukemia | 2023 | https://conductscience.org/library/papers/37803061 | PubMed |
| 17 | 29423093 | Combination of a hypomethylating agent and inhibitors of PARP and HDAC traps PARP1 and DNMT1 to chromatin, acetylates DNA repair proteins, down-regulates NuRD and induces apoptosis in human leukemia and lymphoma cells. | Oncotarget | 2018 | https://conductscience.org/library/papers/29423093 | PubMed |
| 18 | 31623402 | Antileukemic Efficacy in Vitro of Talazoparib and APE1 Inhibitor III Combined with Decitabine in Myeloid Malignancies. | Cancers (Basel) | 2019 | https://conductscience.org/library/papers/31623402 | PubMed |
| 19 | 30213852 | Parp3 promotes long-range end joining in murine cells. | Proc Natl Acad Sci U S A | 2018 | https://conductscience.org/library/papers/30213852 | PubMed |
| 20 | 30039287 | PARP3 inhibitors ME0328 and olaparib potentiate vinorelbine sensitization in breast cancer cell lines. | Breast Cancer Res Treat | 2018 | https://conductscience.org/library/papers/30039287 | PubMed |
Cited by1
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 1 citation.
| PMID | Title | Journal | Year | In Papers |
|---|---|---|---|---|
| 41732388 | Targeting FN1 to overcome gemcitabine resistance in gallbladder cancer: Mechanistic insights and an iRGD-modified PEG-PLGA nanoparticle delivery strategy. | Mater Today Bio | 2026 | https://conductscience.org/library/papers/41732388 |
Source PubMed
Genes4
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| AKT1 | 207 | PubTator's text mining | https://conductscience.org/library/genes/207 | NCBI Gene |
| MTOR | 2475 | PubTator's text mining | https://conductscience.org/library/genes/2475 | NCBI Gene |
| PARP3 | 10039 | PubTator's text mining | https://conductscience.org/library/genes/10039 | NCBI Gene |
| PIK3CB | 5291 | PubTator's text mining | https://conductscience.org/library/genes/5291 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41008918
GET https://conductscience.org/api/papers/v1/41008918/references?page=2